Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | TPO | P07202 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593139 | 0.87 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL2276119 | 0.83 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL1569200 | 0.82 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL2656708 | 0.82 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL1860285 | 0.81 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL17316607 | 0.81 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL17316533 | 0.81 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL2271144 | 0.81 | L3MBTL1 (0.66) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL1859550 | 0.81 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL944098 | 0.80 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0375977-A1 | Oxidation hairdyeing composition based upon diaminopyrazole derivatives, and these diaminopyrazole derivatives | Wella Aktiengesellschaft (DE) | 1990-07-04 | — | — | EP | claimed |
| EP-4656602-A2 | MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES | Entegris, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-117126578-B | Organosilicon polymer/POSS hybrid antifouling coating grafted with antibacterial molecules and preparation method thereof | 中国科学院海洋研究所 | 2025-04-22 | — | — | CN | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| US-20240350984-A1 | MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES | ENTEGRIS, INC. | 2024-10-24 | — | — | US | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| US-12059656-B2 | Membranes for removing metallic species from amines | ENTEGRIS, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | disclosed |
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-101541756-A | Pyrazoles as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009014730-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| US-4482555-A | ANTIINFLAMMATORY, ANTIARTHRITIC AGENTS, AND ANALGESIC | FARMITALIA CARLO ERBA S.P.A. (IT) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | ALDH1A1 3558/4885L3MBTL1 4128/4885TDP1 2453/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | ALDH1A1 1567/4885L3MBTL1 3703/4885TDP1 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.